- ... deficiency disorder; MOI = mode of inheritance; PTH = parathyroid hormone; T 4 = thyroxine; TSH = thyroid-stimulating hormone 1. Medical geneticist, certified genetic counselor, certified advanced ...
- ... involve the pituitary, central endocrine disorders (including growth hormone deficiency, central diabetes insipidus, and hypogonadotropic hypogonadism) are ...
- ... Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency. 2017. Population 208. City of Hope Medical ...
- ... prostate cancer include surgery (radical prostatectomy), radiation therapy, hormone therapy (i.e., androgen deprivation therapy), or ablation ( ... than as monotherapy, reduces the levels of male hormones, or androgens (e.g., testosterone and dihydrosterone) in ...
- ... Drug Treatment Alendronate Zoledronic Acid (Zoledronate) Denosumab Raloxifene Hormone Therapy Other Drugs Investigated for Review Chapter 5. ... Alendronate Zoledronic Acid (Zoledronate) Any Bisphosphonate Denosumab Raloxifene Hormone Therapy Other Drugs Investigated for Review Chapter 6. ...
- ... has relapsed. Some tumors may be associated with hormone secretion—for example, estrogen in granulosa cell tumors ... patients had tumors that were salvaged with chemotherapy. References Schneider DT, Jänig U, Calaminus G, et al.: ...
- ... therapy (37% to 54%, includes primarily chemotherapy and hormone therapy), surgery (2% to 7%), and analgesics (16% ... included patients with a history of chemotherapy (35%), hormone therapy (25%), and bisphosphonate use (34%) (unclear if ...
- ... by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol. 2009; 85 :1434–9. [ PubMed : 19656325 ] ... Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. Expert Opin ...
- ... et al [2011] Agents/Circumstances to Avoid Growth hormone supplementation in the absence of growth hormone deficiency has not been helpful, and in fact ...
- ... between BF and specific cancer subtypes defined by hormone receptor status (e.g., luminal, nonluminal, triple negative). ... control studies). Yes; Breast cancer subtypes defined by hormone receptor status (e.g., Luminal, HER2, triple negative). ...